| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
1 company
Aaron Cowen last filed a Form 4 in March 2023, as 10% Owner at PROK. Aaron Cowen's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Our model assigns Aaron Cowen a below-average insider score of 49/100, based on 3 past trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of +4.1%.
At the last filing, the largest reported position was 4,050,675 shares of PROK. Net of sales, the PROK filings show accumulation of 10,875 shares.
Aaron Cowen has 3 Form 4 filings on record from August 2022 to March 2023, all as Prokidney (PROK), 2022–2023.
The 6 reported transactions were 4 open-market purchases and 2 other transactions.
Counted by filing, the open-market trades come to 2 purchases worth about $83K and no sales.
The largest open-market purchase was 7,007 shares of PROK at an average $6.99 on September 6, 2022, about $49K. Twelve months later PROK was up 18%.
Shares as reported in the last Form 4 for each company; the most recent is from March 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.